Objective: The objective of this study is to show the effectiveness of intravenous immunglobulin (IVIG) in demyelinating polyneuropathics. Method: 29 Guillain-Barre Syndrome (GBS) and 6 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients participated in this study. 23 of 29 GBS patients were observed to have recovered one point in functional scale after the treatment. Recovery was observed in one of the 6 CIDP patients. Results: We suggest IVIG is effective and safe in GBS.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More InfoGot It!
